JP2018504910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504910A5 JP2018504910A5 JP2017540269A JP2017540269A JP2018504910A5 JP 2018504910 A5 JP2018504910 A5 JP 2018504910A5 JP 2017540269 A JP2017540269 A JP 2017540269A JP 2017540269 A JP2017540269 A JP 2017540269A JP 2018504910 A5 JP2018504910 A5 JP 2018504910A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- cell
- receptors
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 141
- 239000012634 fragment Substances 0.000 claims description 54
- 239000000427 antigen Substances 0.000 claims description 50
- 102000036639 antigens Human genes 0.000 claims description 50
- 108091007433 antigens Proteins 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 32
- 102000039446 nucleic acids Human genes 0.000 claims description 29
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 150000007523 nucleic acids Chemical class 0.000 claims description 29
- 102000035025 signaling receptors Human genes 0.000 claims description 27
- 108091005475 signaling receptors Proteins 0.000 claims description 27
- 239000012190 activator Substances 0.000 claims description 21
- 230000003834 intracellular effect Effects 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 18
- 102000006240 membrane receptors Human genes 0.000 claims description 17
- 108020004084 membrane receptors Proteins 0.000 claims description 17
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 16
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 14
- 206010038389 Renal cancer Diseases 0.000 claims description 14
- 201000010982 kidney cancer Diseases 0.000 claims description 14
- 102000004560 Interleukin-12 Receptors Human genes 0.000 claims description 12
- 108010017515 Interleukin-12 Receptors Proteins 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 12
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 10
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 10
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 9
- 108010092867 Transforming Growth Factor beta Receptors Proteins 0.000 claims description 9
- 102000009410 Chemokine receptor Human genes 0.000 claims description 8
- 108050000299 Chemokine receptor Proteins 0.000 claims description 8
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 8
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 8
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 8
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 8
- 102000003675 cytokine receptors Human genes 0.000 claims description 8
- 108010057085 cytokine receptors Proteins 0.000 claims description 8
- 108091008039 hormone receptors Proteins 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000017604 Hodgkin disease Diseases 0.000 claims description 7
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 7
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 7
- 102100037850 Interferon gamma Human genes 0.000 claims description 7
- 108010074328 Interferon-gamma Proteins 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 206010027406 Mesothelioma Diseases 0.000 claims description 7
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 7
- 238000003782 apoptosis assay Methods 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- 108010085650 interferon gamma receptor Proteins 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 208000021039 metastatic melanoma Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 230000005522 programmed cell death Effects 0.000 claims description 7
- 201000000849 skin cancer Diseases 0.000 claims description 7
- 208000008732 thymoma Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 206010046766 uterine cancer Diseases 0.000 claims description 7
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- 210000003757 neuroblast Anatomy 0.000 claims description 6
- 102100027207 CD27 antigen Human genes 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 5
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims description 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 5
- 102000000589 Interleukin-1 Human genes 0.000 claims description 5
- 108010002352 Interleukin-1 Proteins 0.000 claims description 5
- 102000003814 Interleukin-10 Human genes 0.000 claims description 5
- 108090000174 Interleukin-10 Proteins 0.000 claims description 5
- 108010065805 Interleukin-12 Proteins 0.000 claims description 5
- 102000013462 Interleukin-12 Human genes 0.000 claims description 5
- 102000003812 Interleukin-15 Human genes 0.000 claims description 5
- 108090000172 Interleukin-15 Proteins 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- 102000004889 Interleukin-6 Human genes 0.000 claims description 5
- 108010002586 Interleukin-7 Proteins 0.000 claims description 5
- 102000000704 Interleukin-7 Human genes 0.000 claims description 5
- 108090001007 Interleukin-8 Proteins 0.000 claims description 5
- 102000004890 Interleukin-8 Human genes 0.000 claims description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 5
- 210000004700 fetal blood Anatomy 0.000 claims description 5
- 108010074108 interleukin-21 Proteins 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 4
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 3
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 3
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 3
- 101710115256 Alpha-actinin-4 Proteins 0.000 claims description 3
- 102100032959 Alpha-actinin-4 Human genes 0.000 claims description 3
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 3
- 102000015735 Beta-catenin Human genes 0.000 claims description 3
- 108060000903 Beta-catenin Proteins 0.000 claims description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 3
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims description 3
- 108010055191 EphA3 Receptor Proteins 0.000 claims description 3
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 claims description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 3
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 3
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 claims description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 3
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 3
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 3
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 3
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
- 101800001271 Surface protein Proteins 0.000 claims description 3
- 108010002687 Survivin Proteins 0.000 claims description 3
- 108010017842 Telomerase Proteins 0.000 claims description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 3
- 108060008724 Tyrosinase Proteins 0.000 claims description 3
- 102000040856 WT1 Human genes 0.000 claims description 3
- 108700020467 WT1 Proteins 0.000 claims description 3
- 101150084041 WT1 gene Proteins 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- 150000002270 gangliosides Chemical class 0.000 claims description 3
- 238000012737 microarray-based gene expression Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- 102000016914 ras Proteins Human genes 0.000 claims description 3
- 108010014186 ras Proteins Proteins 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 201000002829 CREST Syndrome Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 206010021263 IgA nephropathy Diseases 0.000 claims description 2
- 102100023915 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 206010003230 arteritis Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims description 2
- 230000005784 autoimmunity Effects 0.000 claims description 2
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003027 ear inner Anatomy 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 230000002123 temporal effect Effects 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- -1 ICOS Proteins 0.000 claims 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 claims 1
- 102100030703 Interleukin-22 Human genes 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 230000027455 binding Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 101710185679 CD276 antigen Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110489P | 2015-01-31 | 2015-01-31 | |
| US62/110,489 | 2015-01-31 | ||
| PCT/US2015/058192 WO2016122738A1 (en) | 2015-01-31 | 2015-10-30 | Compositions and methods for t cell delivery of therapeutic molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021011588A Division JP7287990B2 (ja) | 2015-01-31 | 2021-01-28 | 治療用分子のｔ細胞送達のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504910A JP2018504910A (ja) | 2018-02-22 |
| JP2018504910A5 true JP2018504910A5 (enExample) | 2018-12-06 |
| JP7170394B2 JP7170394B2 (ja) | 2022-11-14 |
Family
ID=56544127
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540269A Active JP7170394B2 (ja) | 2015-01-31 | 2015-10-30 | 治療用分子のｔ細胞送達のための組成物および方法 |
| JP2021011588A Active JP7287990B2 (ja) | 2015-01-31 | 2021-01-28 | 治療用分子のｔ細胞送達のための組成物および方法 |
| JP2023085868A Pending JP2023099753A (ja) | 2015-01-31 | 2023-05-25 | 治療用分子のｔ細胞送達のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021011588A Active JP7287990B2 (ja) | 2015-01-31 | 2021-01-28 | 治療用分子のｔ細胞送達のための組成物および方法 |
| JP2023085868A Pending JP2023099753A (ja) | 2015-01-31 | 2023-05-25 | 治療用分子のｔ細胞送達のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10828353B2 (enExample) |
| EP (2) | EP4223873A3 (enExample) |
| JP (3) | JP7170394B2 (enExample) |
| AU (3) | AU2015380397B2 (enExample) |
| CA (2) | CA3248123A1 (enExample) |
| ES (1) | ES2947589T3 (enExample) |
| WO (1) | WO2016122738A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7170394B2 (ja) * | 2015-01-31 | 2022-11-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 治療用分子のｔ細胞送達のための組成物および方法 |
| GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
| US11365237B2 (en) * | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| WO2018094244A1 (en) * | 2016-11-17 | 2018-05-24 | Bluebird Bio, Inc. | TGFβ SIGNAL CONVERTOR |
| SG11201906157YA (en) * | 2017-01-07 | 2019-08-27 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
| US10934336B2 (en) | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| WO2019091478A1 (en) | 2017-11-10 | 2019-05-16 | Chineo Medical Technology Co., Ltd. | Modified immune cells and uses thereof |
| WO2019109980A1 (zh) * | 2017-12-06 | 2019-06-13 | 科济生物医药（上海）有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
| KR20200130709A (ko) | 2018-03-06 | 2020-11-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 전립선-특이 막 항원 car 및 이의 사용 방법 |
| CN110257338B (zh) * | 2018-06-21 | 2022-08-26 | 上海斯丹赛生物技术有限公司 | 嵌合细胞因子受体 |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| EP3947471A4 (en) * | 2019-03-27 | 2023-03-15 | The Trustees of The University of Pennsylvania | TN-MUC1 CHIMERIC ANTIGEN RECEPTOR (CAR) T-LYMPHOCYTE THERAPY |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| AU2022345099A1 (en) * | 2021-09-16 | 2024-05-23 | Gt Biopharma, Inc. | Pd-l1 targeting fusion proteins and methods of use thereof |
| WO2023116637A1 (zh) * | 2021-12-21 | 2023-06-29 | 深圳市菲鹏生物治疗股份有限公司 | 转基因免疫细胞及其构建方法和应用 |
| JP2025513801A (ja) | 2022-04-08 | 2025-04-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多部位受容体及びシグナル伝達複合体 |
| TW202519559A (zh) * | 2023-07-10 | 2025-05-16 | 美商再生元醫藥公司 | 雙特異性PD-L1xCD28抗體及其使用方法 |
| WO2025194364A1 (en) * | 2024-03-20 | 2025-09-25 | Hangzhou Hervor Therapeutics Co., Ltd | ENGINEERED TGFβ RECEPTOR REPURPOSED FOR IL-9 SIGNALING AND USES THEREOF IN IMMUNE CELLS |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| EP0663817B1 (en) | 1993-08-10 | 1999-08-11 | W.L. Gore & Associates, Inc. | Cell encapsulating device |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| WO1996039993A1 (en) | 1995-06-07 | 1996-12-19 | Gore Hybrid Technologies, Inc. | An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| US5626561A (en) | 1995-06-07 | 1997-05-06 | Gore Hybrid Technologies, Inc. | Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| WO1997010807A1 (en) | 1995-09-22 | 1997-03-27 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
| IL115933A0 (en) | 1995-11-09 | 1996-01-31 | Oramir Semiconductor Ltd | Process and apparatus for oblique beam revolution for the effective laser stripping of sidewalls |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1998024893A2 (en) | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| KR100663319B1 (ko) | 1997-04-14 | 2007-01-02 | 마이크로메트 에이지 | 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
| US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
| CA2401327C (en) | 2000-03-03 | 2014-05-06 | Valentis, Inc. | Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use |
| AU4761601A (en) | 2000-04-11 | 2001-10-23 | Genentech Inc | Multivalent antibodies and uses therefor |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US20040014645A1 (en) | 2002-05-28 | 2004-01-22 | Advisys, Inc. | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
| US20050070841A1 (en) | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| US7585960B2 (en) | 2005-05-11 | 2009-09-08 | Theramab Gmbh | Nucleic acids encoding superagonistic anti-CD28 antibodies |
| PL1907424T3 (pl) | 2005-07-01 | 2015-12-31 | Squibb & Sons Llc | Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1) |
| EP1957642A2 (en) | 2005-12-07 | 2008-08-20 | Genetronics, Inc. | Variable volume electroporation chamber and methods therefore |
| EP4032899A1 (en) * | 2007-08-20 | 2022-07-27 | Oncotherapy Science, Inc. | Foxm1 peptide and medicinal agent comprising the same |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| WO2010033949A1 (en) | 2008-09-22 | 2010-03-25 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| JP2013527753A (ja) * | 2010-03-23 | 2013-07-04 | イントレキソン コーポレーション | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 |
| CA2832569A1 (en) | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| EP3915588A1 (en) | 2011-07-29 | 2021-12-01 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
| US9688740B2 (en) | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
| ES2786263T3 (es) * | 2012-07-13 | 2020-10-09 | Univ Pennsylvania | Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico |
| CA2895148C (en) * | 2012-12-14 | 2023-02-28 | Yufang Shi | Methods modulating immunoregulatory effect of stem cells |
| WO2014165707A2 (en) * | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| CN105452287A (zh) * | 2013-04-17 | 2016-03-30 | 贝勒医学院 | 免疫抑制性TGF-β信号转换器 |
| EP3626817B1 (en) * | 2013-07-15 | 2022-09-28 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods of preparing anti-human papillomavirus antigen t cells |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| JP7170394B2 (ja) * | 2015-01-31 | 2022-11-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 治療用分子のｔ細胞送達のための組成物および方法 |
-
2015
- 2015-10-30 JP JP2017540269A patent/JP7170394B2/ja active Active
- 2015-10-30 CA CA3248123A patent/CA3248123A1/en active Pending
- 2015-10-30 US US15/544,816 patent/US10828353B2/en active Active
- 2015-10-30 EP EP23165648.9A patent/EP4223873A3/en active Pending
- 2015-10-30 CA CA2975147A patent/CA2975147C/en active Active
- 2015-10-30 EP EP15880617.4A patent/EP3250681B1/en not_active Revoked
- 2015-10-30 ES ES15880617T patent/ES2947589T3/es active Active
- 2015-10-30 AU AU2015380397A patent/AU2015380397B2/en active Active
- 2015-10-30 WO PCT/US2015/058192 patent/WO2016122738A1/en not_active Ceased
-
2020
- 2020-09-30 US US17/038,676 patent/US12215137B2/en active Active
-
2021
- 2021-01-28 JP JP2021011588A patent/JP7287990B2/ja active Active
- 2021-12-23 AU AU2021290352A patent/AU2021290352B2/en active Active
-
2023
- 2023-05-25 JP JP2023085868A patent/JP2023099753A/ja active Pending
-
2024
- 2024-12-23 US US18/999,784 patent/US20250163132A1/en active Pending
-
2025
- 2025-01-20 AU AU2025200387A patent/AU2025200387A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504910A5 (enExample) | ||
| JP2017533706A5 (enExample) | ||
| JP2017535261A5 (enExample) | ||
| JP2021058196A5 (enExample) | ||
| RU2020114641A (ru) | Молекулы химерных интернализационных рецепторов и способы применения | |
| JP6022667B2 (ja) | 炎症性ヒトＴｈ１７細胞の増殖および機能を決定的に調節するＩＣＯＳ | |
| Berg et al. | Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells | |
| Godfrey et al. | The role of natural killer cells in immunity against multiple myeloma | |
| Kriegsmann et al. | NKT cells—New players in CAR cell immunotherapy? | |
| JP7146397B2 (ja) | 改変γδＴ細胞 | |
| JP2017533707A5 (enExample) | ||
| KR102853978B1 (ko) | 제3 신호 수용체를 포함하는 키메릭 항원 수용체 및 이의 용도 | |
| Shi et al. | Improving the efficacy and safety of engineered T cell therapy for cancer | |
| Jung et al. | CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects | |
| JP2019513347A5 (enExample) | ||
| Shi et al. | Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects | |
| JP2020517259A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| IL314563A (en) | Non-HLA-restricted T-cell receptors and their uses | |
| JP2017535292A5 (enExample) | ||
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| JPWO2020088631A5 (enExample) | ||
| JP2014533928A5 (enExample) | ||
| Mata-Molanes et al. | Cancer immunotherapy with cytokine-induced killer cells | |
| Hu et al. | Natural killer cell-based immunotherapy for cancer: advances and prospects |